2020
Real-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia after Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL)
Hooley I, Maignan K, Jacob A, Medina A, Benderoff L, Chen R, Huntington S. Real-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia after Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL). Blood 2020, 136: 43-44. DOI: 10.1182/blood-2020-137094.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaCurrent equity holderIgG testCD20 mAbsBaseline characteristicsIgG levelsSevere hypogammaglobulinemiaHigher likelihoodCD20 monoclonal antibody therapyLogistic regressionUnknown statusAnti-CD20 therapyFirst-line settingClinical baseline characteristicsReal-world cohortSimilar baseline characteristicsMonoclonal antibody therapyPotential adverse eventsHypothesis-generating studyDe-identified databaseCurrent employmentCD20 administrationCD20 therapyConcurrent chemotherapyIgG testing
2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Huntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797. DOI: 10.1182/blood-2019-122054.Peer-Reviewed Original ResearchFirst-line settingChronic lymphocytic leukemiaFlatiron Health databaseECOG performance statusFirst-line treatmentEarly discontinuationMultivariable logistic regressionPerformance statusIbrutinib discontinuationSpeakers bureauClinical trialsCLL diagnosisCLL therapyLymphocytic leukemiaHealth databasesLogistic regressionBruton tyrosine kinase inhibitorsFirst-line ibrutinibUse of ibrutinibWorse performance statusPoor performance statusRetrospective cohort studyCommunity oncology settingClinical decision support toolCommunity oncology practicesAssociation of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeOverall survivalHMA cyclesHMA therapyProvider experienceCox proportional hazards modelOlder MDS patientsMedian overall survivalPercent of patientsSEER-Medicare dataMultivariate logistic regressionProportional hazards modelHMA initiationClinical outcomesMDS patientsClinical trialsMedian numberHMA treatmentHazards modelPatientsSignificant associationLogistic regressionPopulation-level survivalSurvivalSyndrome
2016
Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database
Mato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Huntington S, Doshi J. Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood 2016, 128: 4773. DOI: 10.1182/blood.v128.22.4773.4773.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaOlder CLL patientsOverall survivalTreatment initiationCox regressionCLL patientsClinical trialsFirst treatmentNovel agentsChlorambucil monotherapyOlder adultsLymphocytic leukemiaMedicare feeClinical practiceLow-income subsidy statusReal-world treatment patternsRecent landmark clinical trialsCLL/SLL patientsLogistic regressionOlder individualsAdvisory CommitteeGilead SciencesReal-world outcome dataAnemia/thrombocytopeniaApproval of ibrutinib